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ABSTRACT 
Purpose: Patients and relatives experiences of behavioural and personality changes following 
brain tumour were assessed to determine whether these changes are more prominent in the 
experience of patients with frontal tumours and their relatives as a first step to evaluate the 
need to develop appropriate support and management of such changes, which have a 
substantial impact on social functioning, and ultimately to improve quality of life.  
Methods:  Patients and relatives rated the patients’ current levels of apathy, disinhibition and 
executive dysfunction on the Frontal Systems Behaviour Scale. Patients also completed the 
Hospital Anxiety and Depression Scale. The data from 28 patients with frontal tumours and 
24 of their relatives, and 27 patients with non-frontal tumours and 25 of their relatives, were 
analysed.  
Results: Patients with frontal tumours rated themselves significantly higher than patients with 
non-frontal tumours on all frontal systems-related behaviours. The number of patients 
reporting clinical levels of difficulty was significantly greater in patients with frontal tumours 
for disinhibition. The ratings of relatives of patients with frontal tumours were significantly 
higher than those of relatives of patients with non-frontal tumours for apathy. Clinically 
significant levels of apathy and executive dysfunction were however reported by at least 40% 
of patients and relatives regardless of tumour location. Clinical levels of anxiety were 
reported by significantly more patients with frontal tumours than those with non-frontal 
tumours. 
Conclusion: Support and management of behavioural and personality change for patients with 
brain tumours and their relatives, regardless of tumour location, would be most appropriate.  
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INTRODUCTION 
 
Brain tumours not only give rise to a range of neurological and physical deficits but also may 
result in personality and behavioural changes.  Thus the social impact of brain tumour has 
particular significance. Difficulties with personality and social behaviour have been 
consistently reported following damage to the frontal lobes [1-4] including lack of insight into 
these personality changes.  Relatives of patients with brain tumours report personality change 
to be one of the factors associated with poor quality of life[5,6].   Although personality change 
is a well-recognized symptom of brain tumour, there are very few studies specifically 
concerned with the impact of a brain tumour on personality and social dysfunction in daily life 
and within the family. 
 
Increasingly evidence suggests that different anatomical regions of the frontal lobes mediate 
different aspects of social behaviour [7].  Lesions in the orbitofrontal cortex are associated 
with emotional lability and mood disturbances [8,9]. Social awareness can also be 
significantly affected, with patients showing reduced concern about or insight into the 
consequences of their behaviour and/or reduced empathy for the impact of their behaviour on 
others[10].  The orbitofrontal cortex also appears important in adhering to social rules and 
conventions; lesions in this area have been associated with disinhibited and socially 
inappropriate behaviour[11].  The dorsolateral cortex plays an important role in mediating 
executive cognitive functions, such as working memory, inhibition, flexibility, problem-
solving, planning, goal-setting, initiation and strategy generation [12,13].  The medial 
prefrontal cortex is associated with motivational aspects of behaviour; lesions here can result 
in apathy[14].  
 
Personality and behavioural change can have devastating functional consequences resulting in 
reduced personal autonomy, unemployment and/or divorce. Executive difficulties with 
organising, initiating, directing, monitoring and controlling interpersonal behaviour can make 
it difficult to function personally and professionally[15,16].  Despite what can be drastic 
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personality changes, patients with frontal tumours may be unaware that their behaviour has 
changed or is socially inappropriate [17,10]. 
Aims 
The primary aim of this study was to measure patients and relatives assessment of behavioural 
and personality changes following diagnosis of the brain tumour and whether these changes 
are more prominent in the experience of patients with brain tumours involving the frontal 
cortex and their relatives. Identifying which groups of patients and/or relatives are more likely 
to report significant changes in personality and behaviour can enable targeted provision of 
appropriate support.  
 
As the frontal lobes play an important role in self-awareness and self-monitoring, it was also 
expected that patients with frontal tumours would show reduced insight into their levels of 
social cognitive functioning compared to their relatives. 
 
METHODS 
Sixty-six adult patients with focal frontal brain tumours and their relatives and 60 adult 
patients with focal tumours not involving the frontal cortex and their relatives were asked to 
participate.  All participants were recruited from the Joint Multi-Disciplinary Neuro-Oncology 
Clinic.  The inclusion criteria were: i) aged 18 years or above, ii) able to give consent, iii) 
having undergone surgery to confirm diagnosis.   
 
There were no exclusion criteria for relatives, the majority (73.4%) of whom were the 
spouse/partner of the patient; 14.3% were the mother/father; 4.1% sister of the patient; 4.1% 
the son and 4.1% the non-relative carer. Demographic and clinical background information 
was obtained for patients from their medical records (see table 1). The majority of patients in 
both the frontal and nonfrontal tumour groups had low-grade tumours (75 and 81% 
respectively).  Lesion localisation was determined on the basis of MRI scan and report from 
the senior neuroradiologist. The temporal and parietal lobes were the most common locations 
for non-frontal tumours, each diagnosed in 33.3% of patients, and 11.1% had temporal-
parietal tumours. All except two of the nonfrontal brain tumour patients had undergone 
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surgery. Thirteen frontal tumour patients had radiotherapy, 7 of these patients also received 
chemotherapy.  Of the 13 nonfrontal patients that had radiotherapy, one also underwent 
chemotherapy.  All participants gave written informed consent prior to participating in the 
study.    
 
Table 1: Demographic and clinical features of patients 
 Frontal Patients (N=28) Non-Frontal Patients (N=27) 
Age years (mean, SD, Range) 50.3 (13.09) 34-75 48.33 (15.10) 21-73 
Male/Female 11/17 11/16 
Time since surgery years (mean, SD, 
Range) 
4.82 (3.04) 2-17 4.50 (2.98) 1-14 
Tumour location 
 Left 
 Right 
 Bifrontal 
 Subcortical 
 
14 
13 
1 
- 
 
12 
14 
- 
1 
Tumour Grade 
 1 
 2 
 3 
 4 
 
5 
16 
4 
3 
 
5 
17 
3 
2 
 
Patients were asked to complete the Frontal Systems Behaviour Scale (FrSBe) and the 
Hospital Anxiety and Depression Scale (HADS). Relatives were asked to complete only the 
FrSBe. Questionnaires were posted to patients and relatives in separate envelopes along with 
stamped addressed envelopes for the return of completed questionnaires.  
 
The Frontal Systems Behaviour Scale [18] is a 46-item behaviour rating scale designed to 
identify and quantify behaviours frequently reported following damage to the frontal systems 
of the brain. It consists of a Self-Rating Form for completion by the patient, and a Family 
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Rating Form completed by a relative who knows the patient well. Respondents are asked to 
rate the current frequency of behaviours (e.g. (Apathy):‘Speaks only when spoken to’; 
(Disinhibition) ‘Talks out of turn, interrupts others in conversations’; (Executive Dysfunction) 
‘Cannot do two things at once’) according to a 5-point Likert-type scale, where 1 = almost 
never, 2 = seldom, 3 = sometimes, 4 = frequently and 5 = almost always. Each rating form 
generates a total score derived from three subscales measuring apathy, disinhibition and 
executive dysfunction.  The FrSBe provides a measure of behaviour both before (i.e. 
premorbid) and after brain damage. 
 
The FrSBe provides normative data for age, gender and education level for individual 
subscale scores and for the Total Score. Raw scores were converted to T Scores (linear 
transformations of the scores obtained in the normative sample, such that the distribution of 
FrSBe scores has a mean of 50 and Standard Deviation of 10). T scores at or above 65 
represent clinically significant levels of symptomatology and T scores of 64 or less indicate 
non-clinical levels. T scores of between 60 and 64 may be interpreted as an indication of 
borderline levels of impairment. For the purpose of the current study, borderline scores were 
classified as ‘clinical’ as having more than 2 levels of classification would result in 
insufficient power for the statistical analyses.   
 
The Hospital Anxiety and Depression Scale (HADS)[19]), was given to measure depressed 
mood, as this has been found to be common in patients with brain tumours and because of the 
behavioural similarities between the syndromes of apathy and depression[20,21]. Although 
less studied in cancer populations, anxiety has also been shown to be prevalent among 
oncology patients [22].  The HADS is a 14-item self-report questionnaire and consists of an 
Anxiety subscale (HADS-A) and a Depression subscale (HADS-D), each containing 7 
intermingled items. Cut-off scores are provided, enabling levels of anxiety and depression to 
be classified as normal, mild, moderate or severe. Scores of <8 classified as ‘normal’, scores 
8-10 as ‘mild’, scores of 11-15 as ‘moderate’ and scores of  15-21 as ‘severe’. For the purpose 
of the current study, normal scores were classified as ‘non-clinical’ and mild, moderate and 
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severe scores as ‘clinical’, as having more than two levels of classification would result in 
insufficient power for the statistical analyses.   
Response rates for patients with frontal tumours and their relatives were 42 and 36%, 
respectively, and for patients with nonfrontal tumours and their relatives’ response rates were 
45 and 42% respectively. Thus, a total of 28 patients with frontal tumours and 24 of their 
relatives completed the questionnaires, of which there were 23 complete patient-relative pairs.  
A total of 27 patients with tumours not involving the frontal cortex and 25 of their relatives 
completed the questionnaires, of which there were 22 patient-relative pairs.    
 
Statistical analysis  
Paired t tests were conducted to compare premorbid with post-illness overall ratings on the 
FrSBe for the frontal and non-frontal patient groups and the respective relatives groups (see 
table 2).  Hochberg [23] corrections were applied to control for type I errors in multiple 
comparisons.   
 
Table 2: FrSBe Total mean rating scores (SD) premorbid and post-illness 
Group N Premorbid Post-illness P value* (1-tailed) 
Frontal 28 
 
92.89 (26.11) 
 
107.14 (29.43) 0.026 
 
Non-frontal 27 79.25 (18.31) 89.59 (26.12) 0.001 
 
Frontal Relatives 24 83.83 (22.11) 100.41 (31.25) 0.024 
 
Non-frontal Relatives 25 79.84 (21.49) 89.28 (23.54) 0.000 
 
 
*Hochberg adjusted p values 
 
Post-illness One-way, independent groups, analyses of variance (ANOVA) were conducted to 
compare levels of apathy, disinhibition, executive function and overall frontal systems-related 
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behaviour reported by patients and their relatives (see Table 3). To examine whether frontal 
patients showed reduced insight, one-way independent groups (relatives of patients with 
frontal tumours vs. patients with frontal tumours and relatives of patients with nonfrontal 
tumours vs. patients with nonfrontal tumours) ANOVAs were conducted to compare FrSBe 
ratings by patients and by their relatives for each frontal systems-related behaviour. Only data 
obtained from complete ‘patient-relative pairs’ were included in these analyses. Clinical vs. 
nonclinical levels on all the measures of the FrSBe for the patients and relatives groups were 
assessed by 2x2 chi-square tests. One-way, independent groups, ANOVAs were performed to 
compare levels of depression and anxiety reported by patients with frontal tumours and those 
with nonfrontal tumours.  In addition, normative test data comparisons were used to classify 
patients’ HADS scores as ‘clinical’ or ‘nonclinical’, and 2x2 chi-square tests were performed 
to compare the number of patients with frontal tumours with the number of patients with 
nonfrontal tumours reporting clinical levels of anxiety and depression.   
Apart from the paired t tests 9where post-illness overall FrSBe score was predicted to be 
higher than premorbid score for all groups), all statistical tests were two-sided with statistical 
significance set at the 0.05 level.   
Results 
Premorbid vs. post-illness FrSBe rating scores 
As expected, the total FrSBe scores for the frontal and nonfrontal patient groups and both 
relatives groups were significantly higher post-illness (See Table 2).  
Post-illness FrSBe rating scores 
Patients with frontal tumours reported significantly higher levels than patients with non-
frontal tumours on all measures; apathy, F (1, 53) = 4.44, p = 0.04; disinhibition, F (1, 53) = 
4.90, p = 0.031; executive dysfunction, F (1, 53) = 4.10, p = 0.048; and total score (overall 
frontal systems-related behaviour), F (1, 53) = 5.46, p = 0.023 (see Table 3). 
The comparisons of ‘patient-relative pairs’ showed no significant difference on any measure 
between the frontal patients group and their relatives or between nonfrontal patients group and 
their relatives.  
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Table 3: FrSBe mean rating scores (standard deviations) 
 Frontal Tumours Non-Frontal Tumours 
FrSBe Score Patients 
 
Relatives 
 
Patients 
 
Relatives 
 
Apathy 
 
33.89 (10.78) 32.04 (12.64) 28.0 (9.92) 25.80  (7.58) 
Disinhibition 
 
31.54 (8.36)       28.17 (6.84) 26.74 (7.68) 25.68 (7.69) 
Executive Dysfunction 41.71(12.97) 40.20 (14.54) 34.85 (12.14) 37.80 (10.99) 
 
Total Score  
 
107.14(29.43) 
 
100.42(31.26) 
 
89.59 (26.13) 
 
89.28 (23.55) 
 
Clinical levels of frontal systems related behaviour 
The number and percentage of patients and relatives in each group reporting clinical or 
nonclinical levels of frontal systems-related behaviours according to their FrSBe rating are 
presented in Table 4. 
There was a trend for more patients with frontal tumours than patients with nonfrontal 
tumours to report clinical levels of al behaviours measured and this reached statistical 
significance for disinhibition: X2 = 5.973, df = 1, and p = 0.015 (see figure 1). 
Although there was a trend for more relatives of patients with frontal tumours than relatives of 
patients with non-frontal tumours reporting clinical levels of apathy and disinhibition this did 
not reach statistical significance (see figure 1).  
 
Although there was a trend for more relatives of patients with nonfrontal tumours than their 
relatives  to report clinical levels of disinhibition, this did not reach statistical significance, 
and there were no significant differences between these patients and their relatives on the 
other measures.  
 10
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 Fig.1 Percentage of patients with clinical levels of Apathy, Disinhibition and Executive 
Dysfunction as rated by patients and relatives 
 
Depression and Anxiety Scores 
 
Patients with frontal tumours scored significantly higher for depression than patients with 
nonfrontal tumours F (1, 52) = 6.35, p = 0.015. There were no significant difference in anxiety 
scores (see Table 5).  
There was no significant difference in the number of patients with frontal tumours and 
patients with non-frontal tumours reporting clinical  levels of depression, but significantly 
more patients with frontal tumours than patients with non-frontal tumours reported clinical 
levels of anxiety (X2 = 8.927, df = 1, p = 0.003). 
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Table 4 Number and % of frontal and non-frontal tumour patients and their respective relatives reporting clinical or 
non-clinical levels of frontal systems-related behaviours on the FrSBe. 
 Apathy Disinhibition Executive 
Dysfunction 
Total 
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Frontal Patients (n=26) 
N 
% 
 
12 
46.2 
 
14 
53.8 
 
15 
57.7 
 
11 
42.3 
 
16 
61.5 
 
10 
38.5 
 
15 
57.7 
 
11 
42.3 
Non-Frontal Patients (n= 25) 
N 
% 
 
10 
40 
 
15 
60 
 
6 
24 
 
19 
76 
 
11 
44 
 
14 
56 
 
11 
44 
 
14 
56 
Relatives of Frontal Patients (n=23) 
N 
% 
 
13 
56.5 
 
 
10 
43.5 
 
12 
52.5 
 
11 
47.8 
 
12 
52.2 
 
11 
47.8 
 
15 
65.2 
 
8 
34.8 
 
Relatives of Non-Frontal Patients 
(n=24) 
N 
% 
 
 
12 
50 
 
 
12 
50 
 
 
10 
41.7 
 
 
14 
58.3 
 
 
13 
54.2 
 
 
11 
45.8 
 
 
11 
45.8 
 
 
13 
54.2 
Two frontal tumour patients; 2 non-frontal patients; 1 relative of frontal tumour patient and 1 relative of non-frontal 
tumour patient were not included in the above analyses due to missing education data. 
 
DISCUSSION 
Pre and post-illness changes in frontal systems-related behaviour were analysed.  As expected, 
patients with frontal tumours and patients with non-frontal tumours and their respective 
relatives report significantly higher levels of overall frontal-system related behaviour post-
illness.   
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Post-illness, patients with frontal lobe tumours reported significantly higher levels of apathy, 
disinhibition and executive dysfunction than patients with non-frontal brain tumours.  
Normative comparisons revealed an overall trend for a greater percentage of frontal than non-
frontal patients to report clinical levels of apathy, disinhibition and executive dysfunction, 
which reached statistical significance for disinhibition. These findings indicate that the 
subjective experience of difficulties with personality and behavioural change is greater for 
patients with frontal tumours than patients with non-frontal tumours and support the evidence 
that the frontal lobes play a key role in mediating various aspects of social functioning [4,11]. 
Furthermore, patients with frontal brain tumours had significantly higher clinical levels of 
disinhibition suggesting that these patients had more problems with inhibitory control.  
 
Importantly, while patients with frontal tumours reported significantly higher levels of all 
behaviours, and a trend was observed for more clinical levels of all frontal-systems-related 
behaviours in patients with frontal tumours than patients with non-frontal tumours, clinical 
levels of apathy and executive dysfunction were also reported in at least 40% of patients with 
non-frontal tumours. Thus, for a substantial proportion of patients with brain tumours there 
are changes in personality and behaviour, regardless of tumour location.  This supports the 
view that although the prefrontal cortex has a critical role in social functioning, the integrity 
of other regions of the brain is necessary for optimal functioning [24]. However, as 
disinhibition was reported in a relatively small proportion (24%) of patients with non-frontal 
tumours, this suggests that disinhibition is more specifically associated with damage to frontal 
areas of the brain.  This lends support to a recent study examining the neural correlates of 
socioemotional disinhibition and executive function in older patients with neurodegenerative 
disease which reported a specific association between orbitofrontal areas and disinhibition 
[25]. 
 
Regarding relatives’ subjective experience of personality and behavioural change following 
brain tumour there was a trend for the relatives of patients with frontal tumours to report 
higher levels of all frontal-systems related behaviour than relatives of those with non-frontal 
tumours. Interestingly, while this trend was significant for all behavioural measures for the 
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frontal patient group, for the relatives of frontal patients this was only significant for apathy. 
Although the behavioural symptoms of apathy and depression can be similar, apathy is best 
characterised as a disorder of motivation rather than mood state per se. Thus, the disturbance 
of mood (e.g. sadness) which is a predominant feature of depression is either absent or only a 
minor feature in frontal systems related apathy[18]. While the frontal brain tumour patients 
had a higher overall score on the depression subscale of the HADS there was no significant 
difference in the number of patients reporting clinical levels of depression between the two 
patient groups. Therefore, the higher levels of apathy reported by the relatives of the frontal 
brain tumour patients is less likley to merely reflect higher levels of depression in these 
patients. 
 
Although there was an overall trend for more relatives of patients with frontal tumours than 
relatives of patients with non-frontal tumours to report clinical levels of apathy and 
disinhibition, these differences did not reach statistical significance. However, clinical levels 
of frontal systems-related behaviours were reported by at least 40% of all relatives, suggesting 
that the subjective experience of brain tumour for a substantial proportion of relatives involves 
clinically significant difficulties with personality and behavioural changes, regardless of 
whether tumour location was frontal or non-frontal.   
 
It was expected that patients with frontal tumours would show reduced insight into their levels 
of personality and behavioural changes compared to their relatives.  However, no significant 
difference was found on any behavioural measure between ratings by patients with frontal 
tumours and by their relatives or between patients with non-frontal tumours and their 
relatives.  One explanation could be that as reduced insight into one’s behaviour is considered 
to be particularly associated with the orbitofrontal cortex [26], this would support the 
contention of precise and dissociable networks between distinct regions and specific distant 
brain regions [27].    In other words different parts of the orbitofrontal cortex are differentially 
involved in insight and disinhibition.  
 
 
 14
Table 5 HADS anxiety and depression scores (means and standard deviations) and number and 
percentage of patients classified as having clinical and non-clinical levels of depression and anxiety 
HADS Score Frontal Patients  
(n=28) 
Non-Frontal  
(n=26) 
Total Patients 
(n=54) 
    
Depression 
 
 Clinical 
 Non-clinical  
6.07 (4.38) 
 
8(28.5%) 
20 (71.4%) 
3.42 (3.20) 
 
4(15.3%) 
22 (84.6%) 
 
 
 
12 (22.2%) 
42 (77.7%) 
Anxiety 
 
 Clinical 
 Non-clinical 
 
9.11 (4.52) 
 
20 (71.4%) 
8(28.5%) 
6.88 (3.94) 
 
8(30.7%) 
18 (69.2%) 
 
 
28 (51.9%) 
26 (48.1%) 
One non-frontal patient did not complete the HADS 
 
Patients with frontal tumours reported significantly higher levels of depression, although the 
rate of clinical levels of depression was not significantly greater than for patients with non-
frontal tumours. This however may reflect the relatively small number of patients with 
clinical levels of depression in both groups (frontal patients n =8; non-frontal patients n=4). 
Depression is an important complication of primary cerebral glioma and is associated with 
reduced quality of life.[20] Our rate of depression in patients with frontal tumours was similar 
to the overall patient-rated measures reported in the review by Rooney et al [20](i.e. 28.5% vs 
27% respectively). Of the 10 studies that used the HADS depression subscale, the mean 
scores in these studies ranged from 3.15 to 6.2. The mean score for patients with frontal 
tumours in our study was 6.1 which is higher than all but one of the studies reported by 
Rooney et al.[20].  For our non-frontal patients the mean score on the HADS depression 
subscale was lower than all but one of the studies reported by Rooney et al. [20].  Although 
there is currently no consistent evidence that tumour location and depression are associated, 
the study by Wellisch et al [28] reported that frontal lobe tumour location was independently 
associated with major depressive disorder using DSM-IV criteria. Our findings lend support to 
a possible relationship between tumour location and depression. However, larger studies 
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investigating the frequency of depression in patients with primary brain tumours are required 
to elucidate the potential association of tumour location in the aetiology of brain-tumour 
associated depression.  
 
Although we found no significant difference in the overall scores on the HADS anxiety 
subscale between the frontal and non-frontal patient groups when the scores were classified as 
clinical and non-clinical, significantly more frontal tumour patients than non-frontal tumour 
patients had clinical levels of anxiety.  Indeed over 71% of the frontal tumour patients 
reported clinical levels of anxiety compared with 30.7% of the non-frontal tumour patients. 
Very few studies have investigated the presence and characteristics of anxiety in patients with 
primary brain tumours.  
 
Very few studies have investigated the presence and characteristics of anxiety in patients with 
primary brain tumours.  However, in a recent study, Arnold et al [22] reported 48% of their 
363 patients with primary brain tumours had current generalized anxiety disorder according to 
the responses on the Modified Brief Patient Health Questionnaire. This rate of anxiety is 
concordant with the overall rate of anxiety of our combined frontal and non-frontal brain 
tumour patients which was 51.9%.  Anxiety and depression have been found to be negatively 
associated with all aspects of quality of life [29]. The high rates of depression and anxiety in 
our patients with frontal brain tumours highlights the importance of assessing the presence of 
neuropsychiatric illness in patients with brain tumours.  The routine use of screening 
instruments for depression and anxiety in patient with brain tumours would inform more 
effective detection and treatment intervention.  The HADS has been considered to be a more 
accurate screening measure of depression in glioma as it minimises somatic symptoms [21].  
 
The neurobehavioural changes following brain tumour reported by a substantial percentage of 
both relatives of and patients with brain tumours in our study highlight the need for support 
and management for relatives as much as patients.  As personality change is one of the t 
factors associated with poor quality of life [5] and over 75% of the patients in our study have 
low-grade tumours and therefore relatively long survival potential treatment is particularly 
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important.  Neurobehavioural changes are challenging for relatives, and not understanding the 
nature of these changes has been associated with more difficulty coping with them [30].  As a 
first step, information regarding potential neuorobehavioural changes including how to 
recognise, understand, predict and manage behaviours that are causing difficulties following 
brain tumour is likely to help both patients and their relatives “make sense” of these often 
challenging behaviours.  In addition, better access to clinical neuropsychologists with 
expertise in cognitive impairment and neurobehavioural changes working within 
multidisciplinary neuro-oncology teams to provide support and to develop and implement 
coping strategies would help patients and their families manage the neurobehavioural sequelae 
of brain tumour and improve their quality of life.  
 
There are several limitations to this study.  First, the sample size is relatively small which 
restricts the extent to which the findings can be generalized.  Second, given the small sample 
size and multiple analyses, there is an increased risk of type 1 error, although Hochberg 
corrections were applied to paired t test analyses to control for type 1 errors in multiple 
comparisons. Third, as this was an exploratory study with a relatively small sample, we did 
not attempt to investigate the relationship between a range of variables including type and 
grade of tumour, education level and potential treatment effects on behavioural changes.  
Future research with larger samples to establish whether particular variables are associated 
with greater neurobehavioural change in patients with brain tumour is required to inform care 
provision.  
Summary 
Little attention has been given to the neurobehavioural changes in patients with brain tumours. 
These results indicate that the subjective experience of a substantial proportion of patients 
with frontal tumours as well as patients with non-frontal brain tumours patients reaches 
clinical levels of difficulties with personality and behavioural changes, which impact on social 
functioning. The present study also reveals high rates of depression and anxiety in patients 
with primary brain tumours.  Routine assessment of depression and anxiety will facilitate 
evidence-based management of depression and anxiety in patients with primary brain tumours 
and ultimately improve quality of life.  
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